Vaisala - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Vaisala provides environmental measurement instruments and continuous monitoring systems for critical life science applications.  Whether you run cleanrooms, laboratories, incubators, environmental test chambers, warehouses, cold chain, or other critical environments in life science, or are responsible for the whole supply chain management, our solutions will help minimize downtime and maximize yield.

Reliable measurement of environmental parameters and fail-safe continuous monitoring with gap-free data is the key to high quality in processes, end products, and safety of people. Vaisala's measurement and monitoring solutions include humidity, temperature, dew point, carbon dioxide, differential and barometric pressure measurement instruments, continuous monitoring and alarming system, validation/mapping system, cold chain monitoring, support and service globally, including ISO17025 accredited calibrations. Vaisala's solutions combine measurement accuracy and stability with data protection in a way that complies with the strictest regulatory requirements.

Vaisala is a global leader in environmental and industrial measurement. Building on 78 years of experience, Vaisala contributes to a better quality of life by providing a comprehensive range of innovative observation and measurement products and services for chosen weather-related and industrial markets. Headquartered in Finland, Vaisala employs approximately 1500 professionals worldwide, serves customers in over 150 countries and has over 30 offices in 16 countries.

For more information visit www.vaisala.com/lifescience

Vaisala Oyj

Website: www.vaisala.com

E-mail: www.vaisala.com/requestinfo
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FindPharma Custom Search

Click here